In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professors of Cardiology University of Oslo Oslo, Norway Visiting Associate Professorship Johns Hopkins University Baltimore, Maryland